Evidence map›Paper›PMID 31443252›Full record

ArticleCancers2019

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial.

Malgorzata Banys-Paluchowski, Sibylle Loibl, Isabell Witzel, Christoph Mundhenke, Bianca Lederer, Christine Solbach, Thomas Karn, Frederik Marmé, Valentina Nekljudova, Christian Schem and 5 more

Abstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Malgorzata Banys-PaluchowskiDepartment of Gynecology and Obstetrics, Asklepios Klinik Barmbek, 22307 Hamburg, Germany.
Sibylle LoiblGerman Breast Group, 63263 Neu-Isenburg, Germany.
Isabell WitzelDepartment of Gynecology, University of Hamburg-Eppendorf, 20251 Hamburg, Germany.
Christoph MundhenkeDepartment of Gynecology and Obstetrics, University of Kiel, 24105 Kiel, Germany.
Bianca LedererGerman Breast Group, 63263 Neu-Isenburg, Germany.ORCID 0000-0002-4512-2226
Christine SolbachDepartment of Gynecology and Obstetrics, University of Frankfurt, 60590 Frankfurt am Main, Germany.
Thomas KarnDepartment of Gynecology and Obstetrics, University of Frankfurt, 60590 Frankfurt am Main, Germany.ORCID 0000-0002-3264-6573
Frederik MarméUniversity Hospital Mannheim, Medical Faculty Mannheim of the Heidelberg University, 68167 Mannheim, Germany.
Valentina NekljudovaGerman Breast Group, 63263 Neu-Isenburg, Germany.
Christian SchemMammazentrum Hamburg, 20357 Hamburg, Germany.
Elmar StickelerDepartment of Gynecology and Obstetrics, RWTH Aachen University, 52074 Aachen, Germany.
Nicholas WillumsenNordic Bioscience, Biomarkers and Research, 2730 Herlev, Denmark.
Morten A KarsdalNordic Bioscience, Biomarkers and Research, 2730 Herlev, Denmark.
Michael UntchDepartment of Gynecology and Obstetrics, Helios Klinikum Berlin-Buch, 13125 Berlin, Germany.
Volkmar MüllerDepartment of Gynecology, University of Hamburg-Eppendorf, 20251 Hamburg, Germany. v.mueller@uke.de.

Funding

Celgene NCT00567554Nordic Bioscience NCT00567554Roche NCT00567554
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast cancerC3MC4Mcollagen degradation markerlapatinibneoadjuvant therapytrastuzumab

Identifiers

PMID31443252
PMCPMC6721504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.